Ongoing treatment with chemical agents that modify immune response (such as azathioprine, methotrexate, mycophenolate or oral cyclophosphamide) can be considered for the small subset of patients that experience recurrent transverse myelitis.[4] Individuals with permanent physical disabilities may benefit from physical therapy, occupational therapy and vocational therapy.[1] FDA-Approved Treatments The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. People who have spinal cord injuries may be more likely to recover from the disorder.[6] Bed rest is often recommended during the initial days and weeks after onset of the disorder, although some people have symptoms that are less severe than others.[3] Based on patient response and test results, additional therapeutic options may be added. Treatment options may include intravenous immunoglobulin (also known as plasmapheresis) or intravenous steroids.[4][5] This therapy involves removing the straw-colored fluid in which blood cells are suspended (plasma) and replacing the plasma loss with special fluids. The segment of the spinal cord that has inflammation (spinal cord puncture) determines the onset of symptoms.[5] Some patients respond very well to intravenous plasma exchange (a drug often used for lymphoma